Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.
(2007) In International Clinical Psychopharmacology 22(1). p.57-61- Abstract
- Some case reports have shown that patients suffering from obsessive-compulsive disorder can be effectively treated with anti-androgenic pharmacological agents with various modes of action. The most effective group of such agents is the long-acting analogues of the gonadotropin-releasing hormone. This investigation was undertaken in order to further elucidate the possibility of using such powerful anti-androgenic agents in the treatment of obsessive-compulsive disorder. Six male patients, all suffering from therapy-resistant obsessive-compulsive disorder, were included in a 48 weeks open-label trial of the long-acting GnRH-analogue triptorelin. Every other week, the patients rated the severity of obsessive-compulsive disorder symptoms by... (More)
- Some case reports have shown that patients suffering from obsessive-compulsive disorder can be effectively treated with anti-androgenic pharmacological agents with various modes of action. The most effective group of such agents is the long-acting analogues of the gonadotropin-releasing hormone. This investigation was undertaken in order to further elucidate the possibility of using such powerful anti-androgenic agents in the treatment of obsessive-compulsive disorder. Six male patients, all suffering from therapy-resistant obsessive-compulsive disorder, were included in a 48 weeks open-label trial of the long-acting GnRH-analogue triptorelin. Every other week, the patients rated the severity of obsessive-compulsive disorder symptoms by means of a visual analogue scale. During the course of the trial, five out of six patients experienced a considerable improvement. The finding gives further support to the contention that anti-androgenic agents are effective in the treatment of obsessive-compulsive disorder. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/164076
- author
- Eriksson, Tomas LU
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- clinical trial, anti-androgens, gonadotropin-releasing hormone, obsessive-compulsive disorder, treatment, triptorelin
- in
- International Clinical Psychopharmacology
- volume
- 22
- issue
- 1
- pages
- 57 - 61
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- wos:000243146000008
- scopus:33845652185
- ISSN
- 1473-5857
- DOI
- 10.1097/01.yic.0000224793.51900.cb
- language
- English
- LU publication?
- yes
- id
- 28e2cb9d-2b63-4b43-91ca-4b32fc03741f (old id 164076)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17159461&dopt=Abstract
- date added to LUP
- 2016-04-01 12:16:54
- date last changed
- 2022-04-05 20:16:57
@article{28e2cb9d-2b63-4b43-91ca-4b32fc03741f,
abstract = {{Some case reports have shown that patients suffering from obsessive-compulsive disorder can be effectively treated with anti-androgenic pharmacological agents with various modes of action. The most effective group of such agents is the long-acting analogues of the gonadotropin-releasing hormone. This investigation was undertaken in order to further elucidate the possibility of using such powerful anti-androgenic agents in the treatment of obsessive-compulsive disorder. Six male patients, all suffering from therapy-resistant obsessive-compulsive disorder, were included in a 48 weeks open-label trial of the long-acting GnRH-analogue triptorelin. Every other week, the patients rated the severity of obsessive-compulsive disorder symptoms by means of a visual analogue scale. During the course of the trial, five out of six patients experienced a considerable improvement. The finding gives further support to the contention that anti-androgenic agents are effective in the treatment of obsessive-compulsive disorder.}},
author = {{Eriksson, Tomas}},
issn = {{1473-5857}},
keywords = {{clinical trial; anti-androgens; gonadotropin-releasing hormone; obsessive-compulsive disorder; treatment; triptorelin}},
language = {{eng}},
number = {{1}},
pages = {{57--61}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{International Clinical Psychopharmacology}},
title = {{Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.}},
url = {{http://dx.doi.org/10.1097/01.yic.0000224793.51900.cb}},
doi = {{10.1097/01.yic.0000224793.51900.cb}},
volume = {{22}},
year = {{2007}},
}